Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection

Virology

Volumn 349, Issue 2, 2006, Pages 276-289

  Xu, Rong ^a   Srivastava, Indresh K ^b   Kuller, LaRene ^c   Zarkikh, Irina ^a   Kraft, Zane ^a   Fagrouch, Zahra ^d   Letvin, Norman L ^e   Heeney, Jonathan L ^d   Barnett, Susan W ^b   Stamatatos, Leonidas ^a,f  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Washington National Primate Research Center   (United States)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV Env gp140; HIV 1SF162; Neutralizing antibodies; SHIV89.6P; T cell responses

Indexed keywords

GLYCOPROTEIN 140; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFECT; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREACTIVITY; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; CD4 LYMPHOCYTE COUNT; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; NEUTRALIZATION TESTS; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SUBUNIT; VIRAL LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33646863044     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.01.043     Document Type: Article

References (42)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
2. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., and Robinson H.L. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76 12 (2002) 6138-6146
3. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McClure H.M., Moss B., and Robinson H.L. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76 15 (2002) 7625-7631
4. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., Wang S., Mboudjeka I., Leung L., Lian Y., Fong A., Buckner C., Ly A., Hilt S., Ulmer J., Wild C.T., Mascola J.R., and Stamatatos L. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75 12 (2001) 5526-5540
5. Barouch H.D., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., Bilska M., Craiu A., Zheng X.X., Krivulka G.R., Beaudry K., Lifton M.A., Nickerson C.E., Trigona W.L., Punt K., Freed D.C., Guan L., Dubey S., Casimiro D., Simon A., Davies M.-E., Chastain M., Strom T.B., Gelman R.S., Montefiori D.C., Lewis M.G., Emini E.A., Shiver J.W., and Letvin N.L. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (2000) 486-492
6. Barouch D.H., Santra S., Kuroda M.J., Schmitz J.E., Plishka R., Buckler-White A., Gaitan A.E., Zin R., Nam J.H., Wyatt L.S., Lifton M.A., Nickerson C.E., Moss B., Montefiori D.C., Hirsch V.M., and Letvin N.L. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75 11 (2001) 5151-5158
7. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
8. Buckner C., Gines L.G., Saunders C.J., Vojtech L., Srivastava I., Gettie A., Bohm R., Blanchard J., Barnett S.W., Safrit J.T., and Stamatatos L. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320 1 (2004) 167-180
9. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D.M., Deers M., Corey L., Greenberg M.L., Schwartz D.H., and Montefiori D.C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16 18 (2000) 2019-2035
10. Casimiro D.R., Tang A., Chen L., Fu T.M., Evans R.K., Davies M.E., Freed D.C., Hurni W., Aste-Amezaga J.M., Guan L., Long R., Huang L., Harris V., Nawrocki D.K., Mach H., Troutman R.D., Isopi L.A., Murthy K.K., Rice K., Wilson K.A., Volkin D.B., Emini E.A., and Shiver J.W. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77 13 (2003) 7663-7668
11. Casimiro D.R., Bett A.J., Fu T.M., Davies M.E., Tang A., Wilson K.A., Chen M., Long R., McKelvey T., Chastain M., Gurunathan S., Tartaglia J., Emini E.A., and Shiver J. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. 78 20 (2004) 11434-11438
12. Etemad-Moghadam B., Karlsson G.B., Halloran M., Sun Y., Schenten D., Fernandes M., Letvin N.L., and Sodroski J. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J. Virol. 72 10 (1998) 8437-8445
13. Feinberg M.B., and Moore J.P. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8 3 (2002) 207-210
14. Harouse J.M., Gettie A., Tan R.C., Blanchard J., and Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284 5415 (1999) 816-819
15. Herrera C., Spenlehauer C., Fung M.S., Burton D.R., Beddows S., and Moore J.P. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77 2 (2003) 1084-1091
16. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., Fuller J.T., Kunstman K.J., Sutter G., Montefiori D.C., Erfle V., Desrosiers R.C., Wilson N., Picker L.J., Wolinsky S.M., Wang C., Allison D.B., and Watkins D.I. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76 14 (2002) 7187-7202
17. Hu S.-L., Abrams K., Barber G.N., Moran P., Zarling J.M., Langlois A.J., Kuller L., Morton W.R., and Benveniste R.E. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255 (1992) 456-459
18. Johnson W.E., Lifson J.D., Lang S.M., Johnson R.P., and Desrosiers R.C. Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J. Virol. 77 1 (2003) 375-381
19. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
20. Luciw P.A., Pratt-Lowe E., Shaw K.E.S., Levy J.A., and Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7490-7494
21. McCaffrey R.A., Saunders C., Hensel M., and Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78 7 (2004) 3279-3295
22. Montefiori D.C., Altfeld M., Lee P.K., Bilska M., Zhou J., Johnston M.N., Gao F., Walker B.D., and Rosenberg E.S. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J. Immunol. 170 7 (2003) 3906-3914
23. Mooij P., Bogers W.M., Oostermeijer H., Koornstra W., Ten Haaft P.J., Verstrepen B.E., Van Der Auwera G., and Heeney J.L. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J. Virol. 74 9 (2000) 4017-4027
24. Patterson L.J., Malkevitch N., Zhao J., Peng B., and Robert-Guroff M. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol. 21 9 (2002) 627-635
25. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., Bolognesi D.P., Fauci A.S., and Montefiori D.C. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176 4 (1997) 924-932
26. Polacino P., Stallard V., Klaniecki J.E., Montefiori D.C., Langlois A.J., Richardson B.A., Overbaugh J., Morton W.R., Benveniste R.E., and Hu S.L. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J. Virol. 73 1 (1999) 618-630
27. Polacino P., Stallard V., Montefiori D.C., Brown C.R., Richardson B.A., Morton W.R., Benveniste R.E., and Hu S.L. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J. Virol. 73 4 (1999) 3134-3146
28. Polacino P.S., Stallard V., Klaniecki J.E., Pennathur S., Montefiori D.C., Langlois A.J., Richardson B.A., Morton W.R., Benveniste R.E., and Hu S.L. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J. Virol. 73 10 (1999) 8201-8215
29. Rasmussen R.A., Hofmann-Lehmann R., Li P.L., Vlasak J., Schmitz J.E., Reimann K.A., Kuroda M.J., Letvin N.L., Montefiori D.C., McClure H.M., and Ruprecht R.M. Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS 16 6 (2002) 829-838
30. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.-W., Karlsson G.B., Sodroski J., and Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70 (1996) 6922-6928
31. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 100 7 (2003) 4144-4149
32. Seaman M.S., Santra S., Newberg M.H., Philippon V., Manson K., Xu L., Gelman R.S., Panicali D., Mascola J.R., Nabel G.J., and Letvin N.L. Vaccine-elicited memory cytotoxic T lymphocytes contribute to mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J. Virol. 79 8 (2005) 4580-4588
33. Seth A., Ourmanov I., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., Wyatt L., Carroll M., Moss B., Venzon D., Letvin N.L., and Hirsch V.M. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) gag-Pol primes for an anamnestic gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74 6 (2000) 2502-2509
34. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., and Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
35. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., Martin L., Vita C., Zhu P., Roux K.H., Vojtech L., C.M. D., Donnelly J., Ulmer J.B., and Barnett S.W. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77 20 (2003) 11244-11259
36. Srivastava I.K., VanDorsten K., Vojtech L., Barnett S.W., and Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77 4 (2003) 2310-2320
37. Stamatatos L., and Cheng-Mayer C. An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 72 (1998) 7840-7845
38. Stamatatos L., Lim M., and Cheng-Mayer C. Generation and structural analysis of soluble oligomeric envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 16 (2000) 981-994
39. Ten Haaft P., Verstrepen B., Uberla K., Rosenwirth B., and Heeney J. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J. Virol. 72 12 (1998) 10281-10285
40. ten Haaft P., Almond N., Biberfeld G., Cafaro A., Cranage M., Ensoli B., Hunsmann G., Polyanskaya N., Stahl-Hennig C., Thortensson R., Titti F., and Heeney J. Comparison of early plasma RNA loads in different macaque species and the impact of different routes of exposure on SIV/SHIV infection. J. Med. Primatol. 30 4 (2001) 207-214
41. Vogel T.U., Allen T.M., Altman J.D., and Watkins D.I. Functional impairment of simian immunodeficiency virus-specific CD8+ T cells during the chronic phase of infection. J. Virol. 75 5 (2001) 2458-2461
42. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., and Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74 15 (2000) 6893-6910